Metabolic consequences of acute and chronic empagliflozin administration in treatment-naive and metformin pretreated patients with type 2 diabetes

被引：0
|
作者：
Elza Muscelli
Brenno Astiarraga
Elisabetta Barsotti
Andrea Mari
Freimut Schliess
Leszek Nosek
Tim Heise
Uli C. Broedl
Hans-Juergen Woerle
Ele Ferrannini
机构：
[1] University of Pisa,Department of Clinical and Experimental Medicine
[2] C.N.R. Institute of Neuroscience,undefined
[3] Profil,undefined
[4] Boehringer Ingelheim Pharma GmbH & Co. KG,undefined
[5] CNR Institute of Clinical Physiology,undefined
来源：
Diabetologia | 2016年 / 59卷
关键词：
Empagliflozin; Endogenous glucose production; Glycosuria; Metformin; Type 2 diabetes;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：700 / 708
页数：8
相关论文
共 50 条
  • [21] Underutilization of Antihyperglycemic Dual Therapy in Eligible, Treatment-Naive Patients With Type 2 Diabetes
    Qiu, Ying
    Fu, Alex Z.
    Davies, Michael J.
    Engel, Samuel S.
    DIABETES, 2012, 61 : A384 - A384
  • [22] Pharmacokinetics of metformin in patients with chronic kidney disease stage 4 and metformin-naive type 2 diabetes
    Dissanayake, Ajith M.
    Wheldon, Mark C.
    Hood, Christopher J.
    PHARMACOLOGY RESEARCH & PERSPECTIVES, 2018, 6 (05):
  • [23] METABOLIC EFFECTS OF METFORMIN ADDITION TO CHRONIC GLIBENCLAMIDE TREATMENT IN TYPE-2 DIABETES
    MARENA, S
    TAGLIAFERRO, V
    MONTEGROSSO, G
    PAGANO, A
    SCAGLIONE, L
    PAGANO, G
    DIABETES & METABOLISM, 1994, 20 (01): : 15 - 19
  • [24] Empagliflozin as add-on to metformin plus sulfonylurea in patients with Type 2 diabetes
    Haering, H. U.
    Merker, L.
    Christiansen, A. Vedel
    Roux, F.
    Salsali, A.
    Kim, G.
    Meinicke, T.
    Woerle, H. J.
    Broedl, U. C.
    DIABETIC MEDICINE, 2015, 32 : 89 - 89
  • [25] Empagliflozin as add-on to metformin plus sulphonylurea in patients with type 2 diabetes
    Haering, Hans-Ulrich
    Merker, Ludwig
    Christiansen, Anita Vedel
    Roux, Flavien
    Salsali, Afshin
    Kim, Gabriel
    Meinicke, Thomas
    Woerle, Hans J.
    Broedl, Uli C.
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2015, 110 (01) : 82 - 90
  • [26] Empagliflozin as add-on to pioglitazone with or without metformin in patients with Type 2 diabetes
    Kovacs, C. S.
    Seshiah, V.
    Merker, L.
    Christiansen, A. Vedel
    Roux, F.
    Salsali, A.
    Kim, G.
    Stella, P.
    Woerle, H. J.
    Broedl, U. C.
    DIABETIC MEDICINE, 2015, 32 : 88 - 88
  • [27] Underutilisation of antihyperglycaemic combination therapy in eligible, treatment-naive patients with type 2 diabetes mellitus
    Qiu, Y.
    Fu, A. Z.
    Davies, M. J.
    Engel, S. S.
    DIABETOLOGIA, 2012, 55 : S405 - S405
  • [28] Vildagliptin plus metformin combination therapy provides superior glycaemic control to individual monotherapy in treatment-naive patients with type 2 diabetes mellitus
    Bosi, E.
    Dotta, F.
    Jia, Y.
    Goodman, M.
    DIABETES OBESITY & METABOLISM, 2009, 11 (05): : 506 - 515
  • [29] SERENADE: rimonabant monotherapy for treatment of multiple cardiometabolic risk factors in treatment-naive patients with Type 2 diabetes
    Rosenstock, J.
    Iranmanesh, A.
    Hollander, P.
    DIABETIC MEDICINE, 2007, 24 : 4 - 4
  • [30] Empagliflozin/metformin fixed-dose combination: a review in patients with type 2 diabetes
    Hu, Jingbo
    Zou, Ping
    Zhang, Shuo
    Zhou, Minzhi
    Tan, Xueying
    EXPERT OPINION ON PHARMACOTHERAPY, 2016, 17 (18) : 2471 - 2477
12345